Supplementary Figure S2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

Q: What type of study is this?

This is a Experimental Study study.

Jack C. Stromatt; Eman Ahmed; Thomas Drabison; Mahesh R. Nepal; Anika T. Chowdhury; Shelley Orwick; Daelynn R. Buelow; Eric D. Eisenmann; Kevin M. Huang; Alex Sparreboom; Sharyn D. Baker

doi:10.1158/2767-9764.30111362

September 12, 2025Open Access

Supplementary Figure S2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

View Full Paper

Ask AI

Bookmark

Share

Key Points

Inhibition of OATP1B1 and OATP1B3 by TL-895 was observed, indicating potential drug-drug interactions.
Mean values and standard deviation were reported from two independent experiments performed in triplicate.
Data were collected using engineered HEK293 cells to assess the effects of varying TL-895 concentrations.
Understanding these interactions may inform clinical implications for safe drug prescribing practices.

Implication

Analysis of TL-895 effects on OATP1B1 and OATP1B3 transport in engineered cells, suggesting interaction risks.

Abstract

Inhibition of OATP1B1 and OATP1B3 by TL-895. Inhibition of EβG transport by OATP1B1 (A) and CCK-8 transport by OATP1B3 (B) in the presence and absence of Varying concentrations of TL-895 in engineered HEK293 cells. Data represent mean values (symbols) and SD (error bars) of 2 independent experiments performed in triplicate.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Stromatt et al. (2025) studied this question.

synapsesocial.com/papers/68d4605131b076d99fa5fb29 https://doi.org/10.1158/2767-9764.30111362

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

Key Points

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S2 from Drug–Drug Interaction Liabilities with BTK Inhibitor TL-895

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading